Form 4: LivaNova PLC Executive Franco Poletti Reports Stock Transactions
SEC Form 4
Franco Poletti, President of Cardiopulmonary at LivaNova PLC, reports the acquisition and disposal of ordinary shares and derivative securities, including restricted stock units (RSUs), performance stock units (PSUs), and stock appreciation rights (SARs).
Summary
- On March 30, 2025, Franco Poletti, President of Cardiopulmonary at LivaNova PLC, reported transactions involving the company's ordinary shares and derivative securities.
- These transactions include the acquisition of 1,257 ordinary shares through the vesting of restricted stock units (RSUs) and the disposal of 542 ordinary shares to cover tax obligations.
- Poletti also acquired and disposed of various RSUs, PSUs, and stock appreciation rights (SARs) under the company's 2015 and 2022 Incentive Award Plans.
- The reported transactions reflect the vesting of previously granted equity awards and the granting of new awards with performance-based and time-based vesting schedules.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but the granting of equity awards can be seen as a positive sign of alignment between management and shareholders.
Positives
- The granting of new RSUs, PSUs, and SARs aligns Poletti's interests with those of the company and its shareholders.
- The performance-based vesting of PSUs incentivizes Poletti to drive improvements in free cash flow, return on invested capital, and total shareholder return.
Risks
- The value of the derivative securities is dependent on the future performance of LivaNova PLC's ordinary shares.
- The vesting of PSUs is contingent upon the company achieving specific performance targets, which may not be met.
Future Outlook
The document outlines future vesting dates for RSUs, PSUs, and SARs, with the vesting of PSUs contingent upon the company's performance relative to targets for free cash flow, return on invested capital, and total shareholder return over the next several years.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It is common for executives to receive equity compensation as part of their overall remuneration, aligning their interests with those of shareholders.
Comparison to Industry Standards
- Equity compensation practices, including the use of RSUs, PSUs, and SARs, are common among publicly traded companies, particularly in the healthcare and medical device industries.
- Companies like Medtronic, Boston Scientific, and Abbott also utilize similar equity-based compensation plans to incentivize their executives.
- The specific vesting schedules and performance metrics used for PSUs can vary depending on the company's strategic goals and industry benchmarks.
Stakeholder Impact
- Shareholders may view the granting of equity awards as a positive sign, aligning management's interests with their own.
- Employees may be motivated by the company's performance-based compensation structure.
- The transactions have a limited direct impact on customers, suppliers, and creditors.
Key Dates
| Date | Description |
|---|---|
| 03/30/2021 | Reporting person was granted RSUs subject to a four-year vesting in equal annual installments. |
| 03/30/2022 | Reporting person was granted RSUs subject to a four-year vesting in equal annual installments. |
| 03/30/2023 | Reporting person was granted RSUs subject to a four-year vesting in equal annual installments. |
| 03/30/2024 | Reporting person was granted RSUs subject to a four-year vesting in equal annual installments. |
| 01/01/2025 | Start date for the three-year performance period for TSR-based PSUs. |
| 03/30/2025 | Date of reported transactions, including vesting of RSUs and granting of new RSUs, PSUs, and SARs. |
| 03/30/2026 | First vesting date for RSUs and SARs granted on March 30, 2025. |
| 12/31/2027 | End date for the three-year performance period for TSR-based PSUs. |
| 03/30/2028 | Vesting or lapse date for PSUs granted on March 30, 2025, based on FCF and ROIC performance. |
| 03/30/2035 | Expiration date for stock appreciation rights granted on March 30, 2025. |
| 04/01/2025 | Date of signature for the Form 4 filing. |
Keywords
LivaNova PLC, Franco Poletti, Form 4, insider trading, restricted stock units, performance stock units, stock appreciation rights, equity compensation, beneficial ownership, securities, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.